Sayeh M Lavasani, MD

Lavasani Sayeh M
Specialties
Breast Medical Oncology
Gender
Female

Primary Office
1150 N 35th Avenue
Suite 170
Hollywood, FL 33021
Phone
954-265-4325
Fax:
954-965-6388

Meet the Physician

Sayeh M. Lavasani, MD, is board certified in medical oncology and internal medicine. After earning her medical degree from Iran University of Medical Sciences in Tehran, Iran, Dr. Lavasani continued her medical training in Ontario, Canada. She completed the Ontario International Medical Graduate Program at the University of Toronto in 2004, the Internal Medicine Postgraduate Program at Queen’s University in Kingston, Ontario in 2007, and the Medical Oncology Postgraduate Program at McMaster University in 2009. Dr. Lavasani went on to complete her postdoctoral fellowship in breast cancer at Sunnybrook Odette Cancer Center at the University of Toronto in 2010. Also in 2010, Dr. Lavasani earned her Master of Science in clinical epidemiology and healthcare research from the Department of Health Policy, Management and Evaluation at the University of Toronto.

After working at Sunnybrook Odette Cancer Center and Juravinski Cancer Center, both in Ontario, Canada, Dr. Lavasani joined department of oncology at Wayne State University in Detroit, Michigan as assistant professor in 2011. She served as a breast medical oncologist at Karmanos Cancer Institute and served in different committees. She also served as the chair of Karmanos Breast Cancer Symposium since 2013. Dr. Lavasani has extensive experience in breast cancer clinical trials and research projects. In 2016, Dr. Lavasani joined Memorial Physician Group and Memorial Breast Cancer Center as a breast medical oncologist.

Research

Professional organizations

  • American Society of Clinical Oncology
  • Canadian Association of Medical Oncologists
  • Canadian/Ontario Medical Association 
  • European Society for Medical Oncology
  • Royal College of Physicians and Surgeons of Canada  

Teaching

  • PD Course - Preceptor Observed H&P (February 2015), Wayne State University, Detroit, Michigan
  • Core Curriculum Lecture for Internal Medicine Residents (2014-2015), Wayne State University, Detroit, Michigan
  • Karmanos Cancer Institute (2013-2015), Wayne State University Annual Breast Cancer Symposium, Program Director
  • Karmanos Cancer Institute (2012-2015), Wayne State University, Detroit, Michigan Co-Director of breast site rotation for medical oncology fellows. Developed a standard sets of objectives for Breast Medical Oncology Rotation at Karmanos Cancer Institute
  • Weekly teaching sessions for medical oncology fellows rotating through breast center
  • Sunnybrook Odette Cancer Center (2009-2011), University of Toronto, Toronto, Ontario, Canada. Teaching medical oncology and internal medicine residents
  • Juravinski Cancer Center (2007-2009), McMaster University, Hamilton, Ontario, Canada, Chief Medical Oncology Resident. Teaching junior medical oncology and internal medicine residents
  • Kingston General Hospital (2005-2007), Queen’s University, Kingston, Ontario, Canada, Senior internal medicine resident. Teaching to senior medical students and junior resident

Publications

  • Handbook for Clinical Trials of Imaging and Image-Guided Interventions, Lavasani, S, Mahinbakht, A, Shields, A. Chapter 2: Clinical Trials of Therapy, 2016.
  • Estrogen and Colorectal Cancer Incidence and Mortality. Lavasani S, Chlebowski RT, Prentice R, Kato I, Wactawski-Wende J , Johnson K,  Young A, Hubbell FA, Mahinbakht A, Simon MS. Cancer 2015 Sep 2;121(18):3261-71
  • Statins and Breast Cancer stage and Mortality in the Women's Health Initiative Cohort.
  • Arun MP, Desai P, Lehman A, Kwan ML, Manson JE, Lavasani S, Wasswertheil-Smoller S, Sarto GE, LeBoff MS, Cauley J, Cote ML, Beebe-Dimmer J, Jay A, Chlebowski RT, Simon MS
  • Cancer Causes and Control 2015, 26 (4):529-539
  • Sex Hormone Associations with Breast Cancer Risk and the Mediation of Randomized Trial Postmenopausal Hormone Therapy Effects. Breast Cancer Research 2014, 16(2): R30, Zhao S, Chlebowski R, Anderson G, Kuller L, Manson J, Gass M, Patterson R, Rohan T, Lane D, Beresford S, Lavasani S, Rossouw J, Prentice R.
  • BMI, Physical activity, and mortality in women diagnosed with ovarian cancer: results from the Women’s Health Initiative Gynecology Oncology 2014, 133(1):4-10. Yang Zhou, Rowan Chlebowski, Michael LaMonte, Jennifer Bea, Lihong Qi, Robert Wallace, Sayeh Lavasani, Brian Walsh, Garnet Anderson, Mara Vitolins, Gloria Sarto, Melinda L. Irwin.
  • The Quality of Reporting Harm Data in Clinical Trials of Adjuvant Trastuzumab in Early Stage Breast Cancer Treatment. Therapeutic Innovation & Regulatory Science. Nov 8, 2013; 48 (3):299-304. Mahinbakht A, Lavasani, S, Guirguis M.
  • Optimizing the Management of HER2-Positive Early Breast Cancer: The Clinical Reality Current Oncology 2010, 17(4):20-33. Verma S, Lavasani S, Mackey J, Pritchard K, Clemons M, Dent S, Latreille J, Lemieux J, Provencher L, Verma Sh, Chia S, Wang B, Rayson D.
  • Continuity Rate of IUD Use in Referrals to Shahre-Ray Health-Medical Centres, Nabz Journal of Medicine 1993, 4(2):25-31. Lavasani, S. M. et al. 

Research and Poster Presentations                                                          

  • Statins and Breast Cancer stage and Mortality in the Women's Health Initiative Cohort. Arun MP, Desai P, Lehman A, Kwan ML, Manson JE, Lavasani S, Wasswertheil-Smoller S, Sarto GE, LeBoff MS, Cauley J, Cote ML, Beebe-Dimmer J, Jay A, Chlebowski RT, Simon MS. San Antonio Breast Cancer Symposium, December 2014 (P6-10-04)
  • Preliminary Examination of the Survivorship Care Planning Checklist among African American and White Breast Cancer Survivors. Thompson H, Alexander G, Eaton E, Eggly S, Walker E, Lavasani S, Goldberg W, Harper F, Smith M, Hooker C. American Society of Preventive Oncology (ASPO); 7th Biennial Cancer Survivorship Research Conference, Atlanta, GA, June 19, 2014
  • Breast Cancer Provider Responses to Survivorship Care Planning Software. Eaton T, Alexander G, Walker E, Goldberg W, Eggly S, Lavasani S, Harper F, Smith M, Hooker C, Thompson H. Poster presented at the 11th Annual Research Symposium of Henry Ford Health System, Detroit, MI, 2014
  • BMI, Physical activity, and mortality in women diagnosed with ovarian cancer: results from the Women’s Health Initiative. Obesity Society's Annual Meeting, November 2013, Abstract T569P
  • Estrogen and Colorectal Cancer Incidence and Mortality in the Women’s Health Initiative Clinical Trial. ASCO Annual Meeting 2013, Abstract 114188. Lavasani et al.
  • Assessment of complete pathologic response (pCR) in HER2+ locally advanced breast cancer patients who have received trastuzumab. ASCO Breast 2011. Lavasani et al.
  • Concurrent vs. sequential administration of adjuvant trastuzumab in early stage breast cancer: A systematic review and meta-analysis. San Antonio Breast Cancer Symposium, December 2010. Lavasani et al.
  • Adjuvant trastuzumab therapy in early stage breast cancers with HER2/neu overexpression and tumors < 1 cm: A systematic review. ASCO Breast 2010; selected for ASCO Merit Award. Lavasani et al. Improved Outcome and Safe Administration of Cisplatin in Ovarian Cancer Patients, Who Respond, But Become Allergic, to Carboplatin. CAMO (Canadian Association of Medical Oncologists), April 2008. Lavasani et al.

Studies

  • NSABP B-54: A Study of Palbociclib in Addition to Standard Endocrine Treatment in Hormone Receptor Positive Her2 Normal Patients with Residual Disease after Neoadjuvant Chemotherapy and Surgery (PENELOPE-B), 2015. Primary Investigator: Sayeh Lavasani
  • NSABP B-52: a Randomized Phase III Trial Evaluating Pathologic Complete Response in Patients with Hormone Receptor Positive, HETR2-Positive., Large Operable and Locally Advanced Breast Cancer Treated with Neoadjuvant Therapy of Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab (TCHP) with or without Estrogen Deprivation, 2014. Primary Investigator: Lawrence Flaherty. Co-Investigator: Sayeh Lavasani
  • INCB 18424-268 (2014-055): A Randomized, Double-blind, Phase 2 Study of Ruxolitinib or Placebo in combination with Capecitabine in subjects with Advanced or Metastatic HER2 negative Breast Cancer, 2014. Primary Investigator: Sayeh Lavasani
  • 2014-083: A Phase II, Single Arm Study of the use of Steroid-based Mouthwash to Prevent Stomatitis in Postmenopausal Women with Advanced or Metastatic Hormone Receptor Positive Breast Cancer Being Treated with Everolimus Plus Exemestane. 2014     
  • 2014-047: A Phase III, Open Label, Randomised, Controlled, Multi-centre Study to Assess the Efficacy and Safety of Olaparib Monotherapy versus Physician's Choice Chemotherapy in the Treatment of Metastatic Breast Cancer Patients with Germline BRCA1/2 Mutations Protocol Status, 2014. Primary Investigator: Michael Simon. Co-Investigator: Sayeh Lavasani
  • B-55/BIG 6-13: A Randomized, Double-Blind, Parallel, Placebo-Controlled Multi-Center Phase III Study to Assess the Efficacy and Safety of Olaparib Versus Placebo as Adjuvant Treatment in Patients with Germline BRCA1/2 Mutations and High risk HER2 Negative Primary Breast Cancer Who Have Completed Definitive Local Treatment and Neoadjuvant or Adjuvant Chemotherapy, 2014. Primary Investigator: Michael Simon. Co-Investigator: Sayeh Lavasani
  • S1202: A Randomized, Placebo-Controlled Phase II Study of Duloxatine for treatment of AI- associated Musculoskeletal Symptoms in Women with Early-Stage Breast, 2013. Primary Investigator: Sayeh Lavasani
  • S0812: A Randomized, Double-blind, Placebo Controlled trial of High Dose Cholecalciferol in Premenopausal Women at High-Risk for Breast Cancer. 2013. Primary Investigator: Sayeh Lavasani
  • MONALEESA-2 (A2301): A randomized, double-blind, placebo-controlled study of LEE011 in combination with letrozole for the treatment of postmenopausal women with hormone receptor positive, Her2 negative, advanced breast cancer who received no prior therapy for advanced disease, 2013. Primary Investigator: Sayeh Lavasani
  • 2013-111: A Phase 1 Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of JNJ-42756493, a pan-Fibroblast Growth Factor Receptor (FGFR) Tyrosine Kinase Inhibitor, in Subjects with Advanced or Refractory Solid Tumors or Lymphoma, 2013. Primary Investigator: Shirish Gadgeel. Co-Investigator: Sayeh Lavasani
  • 2013-165: A Randomized, Multicenter, Open Label, Phase III, Trial Comparing Trastuzumab Plus Pertuzumab Plus a Taxane following Anthracyclines versus Trastuzumab Emtansine Plus Pertuzumab Following Anthracyclines as Adjuvant Therapy in Patients with OperableHER2 positive Primary Breast Cancer (Kaitlin), 2013. Primary Investigator: Lawrence Flaherty. Co-Investigator: Sayeh Lavasani
  • 2013-085 (Katherine): A Randomized, Multi-center, Open-label study to evaluate the safety of Trastuzumab Emtansine versus Trastuzumab as Adjuvant therapy for Patients with HER2/neu positive primary Breast Cancer who have residual tumor present pathologically in the breast or axillary lymph nodes following preoperative therapy, 2013. Primary Investigator: Lawrence Flaherty. Co-Investigator: Sayeh Lavasani
  • S1207: A phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine therapy +/- One Year of Everolimus in Patients with High-Risk, Hormone Receptor-Positive and HER2/neu Negative Breast Cancer. e3 Breast Cancer Study, 2013. Primary Investigator: Lawrence Flaherty. Co-Investigator: Sayeh Lavasani
  • A011104: Effect of Preoperative Breast MRI on Surgical Outcomes, Costs and Quality of Life of Women with Breast Cancer, 2013. Primary Investigator: David Gorski. Co-Investigator: Sayeh Lavasani
  • TDM4370G/BO21977: A Randomized, Multicenter, Phase III, Open-label Study of the Efficacy and Safety of Trastuzumab-MCC-DM1 Vs. Capecitabine + Lapatinib in Patients with HER2-Positive Locally Advanced or Metastatic Breast Cancer who have received prior Trastuzumab-based Therapy, 2012. Primary Investigator: Sayeh Lavasani
  • 2007-050: A Phase II Trial of Biweekly Gemcitabine, Paclitaxel, and Avastin as Frontline Therapy for Metastatic Breast Cancer, 2012. Primary Investigator:  Sayeh Lavasani
  • C-2876: Phase II Study of GW572016 and Tamoxifen in patients with Metastatic Breast Cancer Resistant to Single-Agent Tamoxifen. NCI 6724, 2012
  • 2011-180: A Retrospective Study of Taxane Induced Peripheral Neuropathy Among African American and White Breast Cancer Patients, 2012. Primary Investigator: Sayeh Lavasani
  • Local Protocol – PI: 2008-107: Retrospective Study of Changes in HER2 Status Following Neoadjuvant Chemotherapy for Breast Cancer, 2012. Primary Investigator: Sayeh Lavasani
  • 2010-056: A Phase II Study of Anti-CD3 x Anti-HER2/neu (HER2Bi) Armed Activated T Cells (ATC) after neoadjuvant Chemotherapy in Patients with HER2/neu (0-2+), Hormone Receptor (HR) Negative Stage II-III Breast Cancers, 2012. Primary Investigator:  Lawrence Lum. Co-Investigator:  Sayeh Lavasani
  • 2009-085: A Phase II Study of Anti-CD3 x anti-HER2/neu Armed Activated T Cells after second Line Chemotherapy for Patients with HER2/neu (0, 1+ or 2+)Metastatic Breast Cancers, 2012. Primary Investigator:  Lawrence Lum. Co-Investigator:  Sayeh Lavasani
  • NSABP B-47:  A Randomized Phase III Trial of Adjuvant Therapy Comparing Chemotherapy Alone (Six Cycles of Docetaxel Plus Cyclophosphamide or Four Cycles of Doxorubicin Plus Cyclophosphamide Followed be Weekly Paclitaxel) to Chemotherapy Plus Trastuzumab in Women with Node-Positive or High Risk Node-Negative HER2-Low Invasive Breast Cancer, 2012. Primary Investigator: Lawrence Flaherty. Co-Investigator: Sayeh Lavasani
  • SWOG S1007: A Phase III, Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy +/- Chemotherapy in Patients with 1-3 Positive Nodes, Hormone Receptor-Positive and HER2-Negative Breast Cancer with Recurrence Score RS) of 25 or Less, 2012. Primary Investigator: Lawrence Flaherty. Co-Investigator: Sayeh Lavasani
  • 155-CL-036: A Phase II Multi-Center, Open-Label Randomized Study of YM155 Plus Docetaxel in Subjects with HER2 Negative Metastatic Breast Cancer, 2012. Primary Investigator:  Elaina Gartner. Co-Investigator: Sayeh Lavasani
  • E2108: A Randomized Phase III Trial of the Value of Early Local Therapy for the Intact Primary Tumor in Patients with Metastatic Breast Cancer, 2012. Primary Investigator: Lydia Choi. Co-Investigator: Sayeh Lavasani
  • NCI-110155-MW: The Ultrasound Study of Tamoxifen. Primary Investigator: Peter Littrup. Co-Investigator: Sayeh Lavasani
  • TDM4884g: An Expanded Access, Open-Label Study of Trastuzumab Emtansine Administered Intravenously to Patients HER2 Positive Locally Advanced or Metastatic Breast Cancer, 2012. Primary Investigator: Patricia LoRusso. Co-Investigator: Sayeh Lavasani 
  • 2009-134: A Randomized, Double-blind, Placebo-Controlled Trial of Neratinib (HKI-272) After Trastuzumab in women with Early-Stage HER-2/neu Overexpressed/Amplified Breast Cancer, 2012. Primary Investigator: Lawrence Flaherty. Co-Investigator: Sayeh Lavasani
  • Improving Survivorship Care Planning Among African American Cancer Survivors. Primary Investigator: Haley Thompson, 2012. Co-Investigator: Sayeh Lavasani

Presentations

  • “Neo-adjuvant and Adjuvant Treatment of Breast Cancer,” The Breast Cancer Symposium, Wayne State University School of Medicine, Troy, Michigan, March 7, 2015
  • Breast Cancer for Internal Medicine Residents’ Core curriculum Lecture, Wayne State University, Detroit, Michigan, Feb. 5, 2015        
  • “Komen Detroit Breast Cancer Expert Panel,” Detroit, Michigan, Sept. 17, 2014
  • “SABCS Update, Adjuvant and Neoadjuvant,” Karmanos Breast Cancer Symposium, Wayne State University School of Medicine, Troy, Michigan, March 1, 2014
  • “Treatment of Metastatic Cancer to Bone in Breast Cancer,” Bone Symposium, Karmanos Cancer Institute and Wayne State University School of Medicine, Troy, Michigan, April 27, 2013   
  • “Update in Neo-adjuvant and Adjuvant Treatment of Breast Cancer,” The Breast Cancer Symposium, Wayne State University School of Medicine, Troy, Michigan, March 2, 2013     
  • “A New Approach to Treating Advanced Hormone Receptor Positive, HER2 negative Breast Cancer,” Detroit, Michigan, Nov 13, 2012; and Marquette, Michigan, Oct. 29, 2012  
  • “Guidelines for Breast Cancer Screening,” National Arab American Medical Association & Syrian American Medical society of Michigan Joint CME Symposium, Southfield, Michigan, Oct. 13, 2012
  • “Breast Cancer Awareness Event,” Wayne State University Undergraduate Program, Wayne State University, Detroit, Michigan, April 19, 2012   
  • “Paraneoplastic Syndromes,” Internal medicine residents’ academic half-day, McMaster University, Hamilton, Ontario, Canada, Sept. 2011           
  • “Controversies in the treatment of HER2+ breast cancers,” Faculty candidate seminar, Karmanos Cancer Institute, Wayne State University, Detroit, Michigan, April 2011        
  • “Medical Oncology Emergencies,” Internal medicine residents’ academic half-day, Sunnybrook Hospital, University of Toronto, Toronto, Ontario, Canada, Dec. 2009  
  • “Breast Cancer Stem Cells,” Investigational New Drug Development Rounds, McMaster University, Hamilton, Ontario, Canada, March 2009   
  • “Neoadjuvant therapy in bladder cancer,” Medical oncology journal club, McMaster University
  • Hamilton, Ontario, Canada, March 2009       
  • “Oncotype DX and Breast Cancer,” Medical oncology journal club, McMaster University, Hamilton, Ontario, Canada, July 2008
  • “San Antonio Breast Cancer Symposium Review,” Juravinski Cancer Center, McMaster University, Hamilton, Ontario, Canada, Jan. 2008           
  • “HDAC inhibitors and cancer,” Investigational New Drug Development Rounds, McMaster University, Hamilton, Ontario, Canada, Nov. 2007   
  • “Cetuximab in head and neck Cancer,” Medical oncology journal club, McMaster University, Hamilton, Ontario, Canada, Sept 2007     
  • “Screening in Lung Cancer,” Internal Medicine grand round presentation, Kingston General Hospital, Kingston, Ontario, Canada, May 2007           
  • Internal medicine residents’ journal club, Queen’s University, Kingston, Ontario, Canada, March 2007

Education

Education
  • Tehran Univ Of Medical Science, 1992
Internships
  • University Of Toronto, 2004
Residencies
  • Queens University, 2007, Internal Medicine
Fellowships
  • Mcmaster University, 2009, Oncology
  • University Of Toronto, 2010
Certifications
  • American Board of Internal Medicine-Internal Medicine
  • American Board of Internal Medicine-Oncology

Related Physicians